F. Gómez-García

发表

Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate‐to‐severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

M. Llamas-Velasco, I. García-Doval, J. Carrascosa, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5‐year observational study of clinical practice: 2008–2013 results of the Biobadaderm registry

I. García-Doval, J. Carrascosa, I. Belinchón, 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2012, Archives of dermatology.

Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

M. Llamas-Velasco, R. Botella-Estrada, I. García-Doval, 2020 .

Association between xerostomia, oral and general health, and obesity in adults. A cross-sectional pilot study

P. Gándara-Vila, E. Otero-Rey, A. Blanco-Carrión, 2021, Medicina oral, patologia oral y cirugia bucal.

Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

M. Llamas-Velasco, I. García-Doval, J. Carrascosa, 2021, The Journal of dermatological treatment.

Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.

F. Vanaclocha, I. García-Doval, P. Dávila-Seijo, 2017, The Journal of investigative dermatology.

Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

F. Vanaclocha, I. García-Doval, P. Dávila-Seijo, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate–severe psoriasis in Spain. BIOBADADERM registry

F. Vanaclocha, I. García-Doval, J. Carrascosa, 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.

F. Vanaclocha, M. Llamas-Velasco, J. Carrascosa, 2017, Actas dermo-sifiliograficas.

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

M. Llamas-Velasco, R. Botella-Estrada, I. García-Doval, 2020, Journal of the American Academy of Dermatology.

Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020 .

Changing trends in drug prescription and causes of treatment discontinuation of first biologic over ten years in psoriasis in the spanish biobadaderm registry.

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020, Actas dermo-sifiliograficas.

Long term safety of nine systemic medications for psoriasis: a cohort study using the Biobadaderm Registry.

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2020, Journal of the American Academy of Dermatology.

Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

I. García-Doval, J. Carrascosa, I. Belinchón, 2017, Journal of the American Academy of Dermatology.

Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta‐analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland

R. Stern, L. Naldi, C. Griffiths, 2018, The British journal of dermatology.

Women with moderate‐to‐severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age‐adjusted fertility rate when compared with the general population

R. Botella-Estrada, I. García-Doval, J. Carrascosa, 2019, The British journal of dermatology.

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016

I. García-Doval, C. Ferrándiz, F. Gómez-García, 2018, Actas Dermo-Sifiliográficas (English Edition).

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.

I. García-Doval, C. Ferrándiz, P. de la Cueva-Dobao, 2018, Actas dermo-sifiliograficas.

Body mass index in patients with moderate‐to‐severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

F. Vanaclocha, I. García-Doval, G. Carretero, 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

Cumulative exposure to biologics and risk of cancer in psoriasis patients

I. Feldhamer, I. García-Doval, F. Gómez-García, 2018 .